ARTICLE | Clinical News

BBR 3576: Phase II

June 9, 2003 7:00 AM UTC

NOV said that in an open-label Phase II trial, 15 of 61 evaluable patients with hormone resistant prostate cancer (HRPC) who received 120 mg/m 2 of its BBR 3576 met the primary endpoint of a PSA response. A PSA response was defined as a >=50% decrease in prostate specific antigen (PSA) levels compared to baseline. Among the responding patients, 4 had at least an 80% decrease in PSA levels compared to baseline. Also, 19 of 61 patients had stable disease, defined as no change in PSA compared to baseline. ...